A. SUMMARY This dataset includes unintentional drug overdose death rates by race/ethnicity by year. This dataset is created using data from the California Electronic Death Registration System (CA-EDRS) via the Vital Records Business Intelligence System (VRBIS). Substance-related deaths are identified by reviewing the cause of death. Deaths caused by opioids, methamphetamine, and cocaine are included. Homicides and suicides are excluded. Ethnic and racial groups with fewer than 10 events are not tallied separately for privacy reasons but are included in the “all races” total. Unintentional drug overdose death rates are calculated by dividing the total number of overdose deaths by race/ethnicity by the total population size for that demographic group and year and then multiplying by 100,000. The total population size is based on estimates from the US Census Bureau County Population Characteristics for San Francisco, 2022 Vintage by age, sex, race, and Hispanic origin. These data differ from the data shared in the Preliminary Unintentional Drug Overdose Death by Year dataset since this dataset uses finalized counts of overdose deaths associated with cocaine, methamphetamine, and opioids only. B. HOW THE DATASET IS CREATED This dataset is created by copying data from the Annual Substance Use Trends in San Francisco report from the San Francisco Department of Public Health Center on Substance Use and Health. C. UPDATE PROCESS This dataset will be updated annually, typically at the end of the year. D. HOW TO USE THIS DATASET N/A E. RELATED DATASETS Overdose-Related 911 Responses by Emergency Medical Services Preliminary Unintentional Drug Overdose Deaths San Francisco Department of Public Health Substance Use Services F. CHANGE LOG 12/16/2024 - Updated with 2023 data. Asian/Pacific Islander race/ethnicity group was changed to Asian. 12/16/2024 - Past year totals by race/ethnicity were revised after obtaining accurate race/ethnicity for some decedents that were previously marked as “unknown” race/ethnicity.

We collect data and report statistics on opioid, stimulant, and other substance use and their impact on health and well-being.

A listing of each accidental death associated with drug overdose in Connecticut from 2012 to 2024. A "Y" value under the different substance columns indicates that particular substance was detected. Data are derived from an investigation by the Office of the Chief Medical Examiner which includes the toxicity report, death certificate, as well as a scene investigation. The “Morphine (Not Heroin)” values are related to the differences between how Morphine and Heroin are metabolized and therefor detected in the toxicity results. Heroin metabolizes to 6-MAM which then metabolizes to morphine. 6-MAM is unique to heroin, and has a short half-life (as does heroin itself). Thus, in some heroin deaths, the toxicity results will not indicate whether the morphine is from heroin or prescription morphine. In these cases the Medical Examiner may be able to determine the cause based on the scene investigation (such as finding heroin needles). If they find prescription morphine at the scene it is certified as “Morphine (not heroin).” Therefor, the Cause of Death may indicate Morphine, but the Heroin or Morphine (Not Heroin) may not be indicated. “Any Opioid” – If the Medical Examiner cannot conclude whether it’s RX Morphine or heroin based morphine in the toxicity results, that column may be checked

This dashboard provides in-depth analysis surrounding events and characteristics of individuals who experienced non-fatal and/or fatal opioid overdoses in the District of Columbia. It includes data on ambulance transports for overdoses, fatalities, naloxone distribution, harm reduction efforts and the results of our used syringe testing. Data is aggregated at the neighborhood and ward levels. Data on fatal opioid overdoses will include deaths from 2021-2024. Data on non-fatal opioid overdoses will include incidents from 2021-2024. Note: Fatal opioid overdose data are delayed by approximately 90 days due to toxicological testing.

In 2023, around 72,776 people in the United States died from a drug overdose that involved fentanyl. This was the second-highest number of fentanyl overdose deaths ever recorded in the United States, and a significant increase from the number of deaths reported in 2019. Fentanyl overdoses are now the driving force behind the opioid epidemic, accounting for the majority of overdose deaths in the United States. What is fentanyl? Fentanyl is an extremely potent synthetic opioid similar to morphine, but more powerful. It is a prescription drug but is also manufactured illegally and is sometimes mixed with other illicit drugs such as heroin and cocaine, often without the user’s knowledge. The potency of fentanyl makes it very addictive and puts users at a high risk for overdose. Illegally manufactured fentanyl has become more prevalent in the United States in recent years, leading to a huge increase in drug overdose deaths. In 2022, the rate of drug overdose death involving fentanyl was 22.7 per 100,000 population, compared to a rate of just one per 100,000 population in the year 2013. Fentanyl overdoses by gender and race/ethnicity As of 2022, the rate of drug overdose deaths involving fentanyl in the United States is over two times higher among men than women. Rates of overdose death involving fentanyl were low for both men and women until around the year 2014 when they began to quickly increase, especially for men. In 2022, there were around 19,880 drug overdose deaths among women that involved fentanyl compared to 53,958 such deaths among men. At that time, the rate of fentanyl overdose deaths was highest among non-Hispanic American Indian or Alaska Natives and lowest among non-Hispanic Asians. However, from the years 2014 to 2018, non-Hispanic whites had the highest fentanyl overdose death rates.

This dashboard provides in-depth analysis surrounding events and characteristics of individuals who experienced non-fatal and/or fatal opioid overdoses in the District of Columbia. It includes data on ambulance transports for overdoses, fatalities, naloxone distribution, harm reduction efforts and the results of our used syringe testing. Data is aggregated at the neighborhood and ward levels. Data on fatal opioid overdoses will include deaths from 2021-2024. Data on non-fatal opioid overdoses will include incidents from 2021-2024. Note: Fatal opioid overdose data are delayed by approximately 90 days due to toxicological testing.

In King County, Washington, the highest number of overdose deaths between 2019 and 2024 occurred in houses that were privately owned or rented. However, in 2023, around 316 drug overdose deaths occurred in a location not meant for human habitation or emergency shelter, representing 24 percent of all drug overdose deaths that year. This statistic depicts the number of drug overdose deaths in King County, Washington between 2019 and 2024, by housing status.

According to Cognitive Market Research, the Global Opioids Market Size will be USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031.

  The global opioid market will expand significantly by XX% CAGR between 2024 and 2030.
  The Pain Relief segment accounts for the largest market share and is anticipated to a healthy growth over the approaching years.
  The hospital pharmacies had a market share of about XX% in 2023.
  The Extended Release /Long-Acting Opioids holds the largest share and is expected to grow in the coming years as well.
  The injectable segment is the market's largest contributor and is anticipated to expand at a CAGR of XX% during the projected period.
  The oxycodone segment holds the largest share and is expected to grow in the coming years as well.
  North America region dominated the market and accounted for the highest revenue of XX% in 2023 and it is projected that it will grow at a CAGR of XX% in the future.

Market Dynamics of the Opioids

Rising prevalence of chronic pain conditions globally

The increased prescription of painkillers during post-operative procedures and an increase in patients with terminally chronic pain or diseases including HIV, and severe cough brought on by lung infections are two causes that are anticipated to increase opioid use as a pain reliever. Chronic pain affects an estimated 20% of the global population, with conditions such as arthritis, cancer, and lower back pain contributing to the growing demand for effective pain management solutions. In the past, it resulted in a demand surge for opioids and boosted growth. Another factor for the growth of the opioid drug market is the spike in the number of surgeries. According to the National Health Interview Survey (NHIS) conducted by the Centers for Disease Control and Prevention (CDC) in 2019, the prevalence of high-impact chronic pain in the United States was 7.4 percent.

(Source-https://www.cdc.gov/nchs/data/databriefs/db390-H.pdf)

The aging population’s vulnerability is at high risk of chronic diseases such as cardiovascular diseases, arthritis, and cancer due to the high comorbid conditions. Declining fertility and mortality rates are some factors contributing to the geriatric population's rise. The impact of chronic pain increases with age and is highest among adults aged 65 years and above. Therefore, the rising geriatric population is anticipated to increase the demand for opioid drugs to manage chronic pain. According to the World Health Organization (WHO), the geriatric population increased from 1.0 million in 2020 to 1.4 million in 2021.

(Source-https://www.who.int/news-room/fact-sheets/detail/ageing-and-health)

Opioid addiction and its side effects pose significant challenges to the market

One of the major challenges for this market is the high potential for abuse and addiction, physicians have scaled back their pain management prescriptions, decreasing global scales. The rising prevalence of opioid abuse is expected to stifle market growth, as practitioners are hesitant to prescribe opioids as pain relievers. The patient may become tolerant and need more and more drugs to achieve the effect of smoothing the pain. Moreover, using opioids for an extended period can develop a dependency, and after leaving the drug, the patient may suffer from withdrawal symptoms such as anxiety, irritability, drug cravings, tremors (shaking), and others. The heightened regulatory scrutiny has resulted in stricter guidelines for prescribing opioids, impacting accessibility for patients in genuine need of pain relief. Regulatory changes often aim to strike a balance between ensuring access for patients and preventing misuse. The forecasted period illustrates a decrease in the opioid market growth due to the adversities and the negative effects of opioids. Researchers and experts have considered this and are making constant efforts to reduce and minimize the negative side effects of opioids. As per the record, drug overdose in the year 2018, had 657 deaths.

(Source-https://www.mass.gov/doc/opioid-related-overdose-deaths-among-ma-residents-august-2018/download)

Furthermore, the Millennium Health's Signals report (2020) revealed that there was a rise in non-prescribe...

West Virginia is currently the state with the highest drug overdose death rate in the United States, with 82 deaths per 100,000 population in 2023. Although West Virginia had the highest drug overdose death rate at that time, California was the state where the most people died from drug overdose. In 2023, around ****** people in California died from a drug overdose. The main perpetrator Opioids account for the majority of all drug overdose deaths in the United States. Opioids include illegal drugs such as heroin, legal prescription drugs like oxycodone, and illicitly manufactured synthetic drugs like fentanyl. The abuse of opioids has increased in recent years, leading to an increased number of drug overdose deaths. The death rate from heroin overdose hit an all-time high of *** per 100,000 population in 2016 and 2017, but has decreased in recent years. Now, illicitly manufactured synthetic opioids such as fentanyl account for the majority of opioid overdose deaths in the United States. Opioid epidemic The sharp rise in overdose deaths from opioids has led many to declare the United States is currently experiencing an opioid epidemic or opioid crisis. The causes of this epidemic are complicated but involve a combination of a rise in dispensed prescriptions, irresponsible marketing from pharmaceutical companies, a lack of physician-patient communication, increased social acceptance of prescription drugs, and an increased supply of cheap and potent heroin on the streets.

The data files from this project are not available through NAHDAP/ICPSR. For information about accessing the data from this project, please contact the Principal Investigator. Feedback from Tribal communities were gathered about a future Tribally specific near real-time opioid overdose monitoring dashboard. A questionnaire about an example dashboard with questions about overdose information, Narcan usage, and feedback about the dashboard's uses were included.

Annual number of deaths registered related to drug poisoning in England and Wales by sex, region and whether selected substances were mentioned anywhere on the death certificate, with or without other drugs or alcohol, and involvement in suicides.

In August 2024, *** non-fatal drug overdoses were reported among drug users who visited supervised consumption sites (SCS) in Canada, an increase from the previous month. This statistic illustrates the number of non-fatal drug overdoses reported monthly on SCS in Canada from March 2020 to August 2024.

The graph illustrates the number of deaths from fentanyl in the United States from 1999 to 2022. The x-axis represents the years, spanning from '99 to '22, while the y-axis displays the annual number of fentanyl-related fatalities. Over this 24-year period, deaths rise dramatically from 730 in 1999 to a peak of 73,838 in 2022. Notable milestones include an increase to 1,742 deaths in 2005, a significant jump to 9,580 in 2015, and a sharp escalation to 70,601 deaths by 2021. The data reveals a consistent and severe upward trend in fentanyl-related deaths, particularly accelerating in the mid-2010s. This information is presented in a line graph format, effectively highlighting the dramatic increase in fatalities due to fentanyl across the United States over the specified years.

The global opioid overdose treatment market is valued at US$ 1.54 billion in 2024, as revealed in a newly published report by Fact.MR. Over the assessment period (2024 to 2034), the market is forecasted to advance at a CAGR of 7.2% and reach a US$ 3.1 billion by the end of 2034.

Report Attribute	Detail
Opioid Overdose Treatment Market Size (2024E)	US$ 1.54 Billion
Forecasted Market Value (2034F)	US$ 3.1 Billion
Global Market Growth Rate (2024 to 2034)	7.2% CAGR
Market Share of Rehabilitation Centers (2034F)	29.7%
North America Market Share (2034F)	43.9%
India Market Growth Rate (2024 to 2034)	11.2% CAGR
Key Companies Profiled	Amneal Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Biotoscana; Collegium Pharmaceutical; EMS Pharma; Endo International; Ethypharm; Eurofarma; GlaxoSmithKline; Hikma Pharmaceuticals; Johnson & Johnson; Mallinckrodt Pharmaceuticals; Mundipharma; Mylan; Novartis; Pfizer; Purdue Pharma; Sanofi; Stada Arzneimittel; Takeda; Teva Pharmaceuticals.

Country-wise Insights

Attribute	United States
Market Value (2024E)	US$ 577.1 Million
Growth Rate (2024 to 2034)	7.8% CAGR
Projected Value (2034F)	US$ 1.22 Billion

Attribute	Japan
Market Value (2024E)	US$ 70.5 Million
Growth Rate (2024 to 2034)	2.8% CAGR
Projected Value (2034F)	US$ 93.2 Million

Category-wise Insights

Attribute	Opioid Antagonists
Segment Value (2024E)	US$ 502.2 Million
Growth Rate (2024 to 2034)	7.8% CAGR
Projected Value (2034F)	US$ 1.06 Billion

Attribute	Naloxone
Market Value (2024E)	US$ 489.5 Million
Growth Rate (2024 to 2034)	8.6% CAGR
Projected Value (2034F)	US$ 1.11 Billion

Attribute	Rehabilitation Centers
Segment Value (2024E)	US$ 460.1 Million
Growth Rate (2024 to 2034)	7.2% CAGR
Projected Value (2034F)	US$ 920.5 Million

This is historical data. The update frequency has been set to "Static Data" and is here for historic value. Updated on 8/14/2024 Drug-Induced Death Rate - This indicator shows the drug-induced death rate per 100,000 population. Drug-induced deaths include all deaths for which illicit or prescription drugs are the underlying cause. In 2007, drug-induced deaths were more common than alcohol-induced or firearm-related deaths in the United States. Between 2012-2014, there were 2793 drug-induced deaths in Maryland. Link to Data Details

A. SUMMARY This dataset comes from the San Francisco Emergency Medical Services Agency and includes all opioid overdose-related 911 calls responded to by emergency medical services (ambulances). The purpose of this dataset is to show how many opioid overdose-related 911 calls the San Francisco Fire Department and other ambulance companies respond to each week. This dataset is based on ambulance patient care records and not 911 calls for service data. B. HOW THE DATASET IS CREATED The San Francisco Fire Department and other ambulance companies send electronic patient care reports to the California Emergency Medical Services Agency for all 911 calls they respond to. The San Francisco Emergency Medical Services Agency (SF EMSA) has access to the state database that includes all reports for 911 calls in San Francisco County. In order to identify overdose-related calls that resulted in an emergency medical service (or ambulance) response, SF EMSA filters the patient care reports based on set criteria used in other jurisdictions called The Rhode Island Criteria. These criteria filter calls to only include those calls where EMS documented that an opioid overdose was involved and/or naloxone (Narcan) was administered. Calls that do not involve an opioid overdose are filtered out of the dataset. Calls that result in a patient death on scene are also filtered out of the dataset. This dataset is created by copying the total number of calls each week when the state makes this data available. C. UPDATE PROCESS Data is generally available with a 24-hour lag on a weekly frequency but the exact lag and update frequency is based on when the State makes this data available. D. HOW TO USE THIS DATASET This dataset includes the total number of calls a week. The week starts on a Sunday and ends on the following Saturday. This dataset will not match the Fire Department Calls for Service dataset, as this dataset has been filtered to include only opioid overdose-related 911 calls based on electronic patient care report data. Additionally, the Fire Department Calls for Service data are primarily based on 911 call data (i.e. calls triaged and recorded by San Francisco’s 911 call center) and not the finalized electronic patient care reports recorded by Fire Department paramedics. E. RELATED DATASETS Fire Department Calls for Service San Francisco Department of Public Health Substance Use Services Unintentional Overdose Death Rates by Race/Ethnicity Preliminary Unintentional Drug Overdose Deaths F. CHANGE LOG 1/17/2024 - updated date/time fields from Coordinated Universal Time (UTC) to Pacific Time (PT) which caused a slight change in historic case counts by week.

This dataset is deprecated and will be removed by the end of the calendar year 2024. Updated on 8/18/2024 Drug and alcohol-related Intoxication death data is prepared using drug and alcohol intoxication data housed in a registry developed and maintained by the Vital Statistics Administration (VSA) of the Maryland Department of Health and Mental Hygiene (DHMH). The methodology for reporting on drug-related intoxication deaths in Maryland was developed by VSA with assistance from the DHMH Alcohol and Drug Abuse Administration, the Office of the Chief Medical Examiner (OCME) and the Maryland Poison Control Center. Assistance was also provided by authors of a 2008 Baltimore City Health Department report on intoxication deaths. Data in this table is by incident location, where the death occurred, rather than by county of residence.

This brief communicates trends in Nitazenes from 2019-2022, a group of powerful illicit opioids that have been linked to overdose deaths in TN.

Snapshot img

What is the Size of Opioid Rescue Products Market?

The opioid rescue products market size is forecast to increase by USD 1.69 billion, at a CAGR of 11.6% between 2023 and 2028. The market is experiencing significant growth due to the escalating opioid overdose crisis in the US. According to the National Institute on Drug Abuse, over 130 Americans die daily from an opioid overdose. In response, the opioid industry is focusing on the development and approval of new drugs to address this public health concern. For instance, sublingual tablets and transdermal patches are gaining popularity as they offer quicker relief and improved treatment access for patients suffering from opioid overdoses. However, challenges persist, including the presence of counterfeit drugs and the management of comorbid illnesses such as constipation, which are common in opioid users. The approval of new drugs and the continued innovation in delivery systems will be crucial in addressing these challenges and reducing opioid-related deaths.

Request Free Opioid Rescue Products Market Sample

Market Segmentation

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.

Distribution Channel

  Offline
  Online


Product Type

  Naloxone
  Naltrexone
  Others


Geography

  North America

    US


  Europe

    Germany
    UK
    France
    Spain


  Asia

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

Which is the Largest Segment Driving Market Growth?

The offline segment is estimated to witness significant growth during the forecast period. Opioid rescue products, such as naloxone and naltrexone, play a crucial role in reversing the effects of opioid overdoses and treating opioid addiction. Pharmacies serve as essential distribution channels for these medications, making them easily accessible to the public. Prescriptions and, in certain cases, over-the-counter sales are options for obtaining these life-saving drugs.

Get a glance at the market share of various regions Download the PDF Sample

The offline segment was valued at USD 896.70 million in 2018. Major pharmacy chains significantly contribute to making opioid rescue products readily available. First responders, including paramedics, police officers, emergency medical technicians, and non-emergency medical personnel, are increasingly utilizing opioid rescue products. These professionals are often the first on the scene during an opioid overdose and can administer immediate intervention, which is vital in preventing fatalities. Non-governmental organizations also play a significant role in increasing awareness and providing training on the use of opioid rescue products to first responders and the general public.

Which Region is Leading the Market?

For more insights on the market share of various regions Request Free Sample

North America is estimated to contribute 46% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. The opioid crisis is a major public health concern in North America, affecting both the United States and Canada. In the United States, during the 12 months ending in February 2023, over 105,000 reported opioid overdoses occurred, primarily due to synthetic opioids like illicit fentanyl. This startling figure highlights the importance of having effective opioid rescue products available to counteract the potentially fatal consequences of opioid overdoses. In Canada, the opioid overdose crisis continues to pose a significant threat to individuals, families, and communities. This crisis is considered one of the most severe public health crises in the country's recent history. Between January 2016 and June 2022, there were approximately 32,600 apparent opioid toxicity deaths. Opioid overdoses can lead to respiratory depression and psychological problems, making it crucial to have accessible and efficient opioid rescue products.

Opioid rescue products, such as naloxone and buprenorphine, play a vital role in reversing opioid overdoses. These medications can help restore normal breathing and prevent further harm. The ongoing opioid crisis necessitates the continuous development and availability of these essential treatments. In conclusion, the opioid crisis is a pressing issue in North America, with the US and Canada experiencing high numbers of opioid overdoses and fatalities. Effective opioid rescue products, like naloxone and buprenorphine, are essential in mitigating the devastating effects of opioid overdoses. It is crucial to ensure these treatments are accessible and readily available to those in need.

How do Technavio's company ranking

In 2022, those aged between 35 and 44 years had the highest number of drug overdose deaths in the United States, with 27,583 deaths. Opioids are the main driver of overdose deaths in the United States. This statistic presents the number of drug overdose deaths in the U.S. from 2013 to 2022, by age group.